If you have been reading about preclinical model and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Rusfertide, sold under the brand name Mimrylo, is a medication used for the treatment of polycythemia vera. It is a hepcidin mimetic. It was developed by Protagonist Therapeutics in partnership with Takeda Pharmaceuticals. It is given by subcutaneous injection. The most common adverse reactions include injection site reactions and anemia. Rusfertide was approved for medical use in the United States in August 2026. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body.
== Pre-atomic chemistry == Working in the late 17th century, Robert Boyle developed the concept of a chemical element as substance different from a compound. Near the end of the 18th century, a number of important developments in chemistry emerged without referring to the notion of an atomic theory. The first was Antoine Lavoisier who showed that compounds consist of elements in constant proportion, redefining an element as a substance which scientists could not decompose into simpler substances by experimentation. This brought an end to the ancient idea of the elements of matter being fire, earth, air, and water, which had no experimental support. Lavoisier showed that water can be decomposed into hydrogen and oxygen, which in turn he could not decompose into anything simpler, thereby proving these are elements. Lavoisier also defined the law of conservation of mass, which states that in a chemical reaction, matter does not appear nor disappear into thin air; the total mass remains the same even if the substances involved were transformed. In 1797 the French chemist Joseph Proust established the law of definite proportions, which states that if a compound is broken down into its constituent chemical elements, then the masses of those constituents will always have the same proportions by weight, regardless of the quantity or source of the original compound. This definition distinguished compounds from mixtures.
"…capitalism as a system has coexisted with and in on occasion sponsored feudalism, monarchy, fascism, slavery, apartheid, and under development. It has also been the great engine of progress, development and innovation in a certain few heartland countries. This means that it must be a system studied as a system and not as an idea. Its claims to be the sponsor of freedom are purely contingent. It's good propaganda but it's not very good political science…"
Its polyanionic structure can mimic nucleic acids like DNA and RNA, making it useful for purification of nucleic acid-binding proteins including DNA and RNA polymerases and transcription factors. Heparin's specific affinity for VSV-G, a viral envelope glycoprotein often used to pseudotype retroviral and lentiviral vectors for gene therapy, allows it to be used for downstream purification of viral vectors. Heparin is being trialed in a nasal spray form as prophylaxis against COVID-19 infection. Furthermore, its reported from trials that due to anti-viral, anti-inflammatory and its anti-clotting effects its inhalation could improve at a 70% rate on patients that were actively struck by a COVID-19 infection.
Sources: en.wikipedia.org
== BP in Positron Emission Tomography == BP is a pivotal measure in the use of positron emission tomography (PET) to measure the density of "available" receptors, e.g. to assess the occupancy by drugs or to characterize neuropsychiatric diseases (yet, one should keep in mind that binding potential is a combined measure that depends on receptor density as well as on affinity). An overview of the related methodology is e.g. given in Laruelle et al. (2002). Estimating BP with PET usually requires that a reference tissue is available. A reference tissue has negligible receptor density and its distribution volume should be the same as the distribution volume in the target region if all receptors were blocked. Although the BP can be measured in a relatively unbiased way by measuring the whole time course of labelled ligand association and blood radioactivity, this is practically not always necessary. Two other common measures have been derived, which involve assumptions, but result in measures that should correlate with BP:
== Cause == The most common underlying pathology leading to TIA and stroke is a cardiac condition called atrial fibrillation, where poor coordination of heart contraction may lead to the formation of a clot in the atrial chamber that can become dislodged and travel to a cerebral artery. Unlike in stroke, the blood flow can become restored prior to infarction which leads to the resolution of neurologic symptoms. Another common culprit of TIA is an atherosclerotic plaque located in the common carotid artery, typically by the bifurcation between the internal and external carotids, that becomes an embolism to the brain vasculature similar to the clot in the prior example. A portion of the plaque can become dislodged and lead to embolic pathology in the cerebral vessels. In-situ thrombosis, an obstruction that forms directly in the cerebral vasculature unlike the remote embolism previously mentioned, is another vascular occurrence with possible presentation as TIA. Also, carotid stenosis secondary to atherosclerosis narrowing the diameter of the lumen and thus limiting blood flow is another common cause of TIA. Individuals with carotid stenosis may present with TIA symptoms, thus labeled symptomatic, while others may not experience symptoms and be asymptomatic.
AMM designs have diversified significantly since the early days of the field. A major route is the introduction of bistability to produce molecular switches, featuring two distinct configurations for the molecule to convert between. This has been perceived as a step forward from the original molecular shuttle which consisted of two identical sites for the ring to move between without any preference, in a manner analogous to the ring flip in an unsubstituted cyclohexane. If these two sites are different from each other in terms of features like electron density, this can give rise to weak or strong recognition sites as in biological systems — such AMMs have found applications in catalysis and drug delivery. This switching behavior has been further optimized to acquire useful work that gets lost when a typical switch returns to its original state. Inspired by the use of kinetic control to produce work in natural processes, molecular motors are designed to have a continuous energy influx to keep them away from equilibrium to deliver work. Various energy sources are employed to drive molecular machines today, but this was not the case during the early years of AMM development. Though the movements in AMMs were regulated relative to the random thermal motion generally seen in molecules, they could not be controlled or manipulated as desired. This led to the addition of stimuli-responsive moieties in AMM design, so that externally applied non-thermal sources of energy could drive molecular motion and hence allow control over the properties.
The Space Race (Russian: космическая гонка, romanized: kosmicheskaya gonka, IPA: [kɐsˈmʲitɕɪskəjə ˈɡonkə]) was a 20th-century competition between the Cold War rivals, the United States and the Soviet Union, to achieve superior spaceflight capability. It had its origins in the ballistic missile-based nuclear arms race between the two nations that followed World War II and the onset of the Cold War. The technological advantage demonstrated by spaceflight achievement was seen as necessary for national security, particularly in regard to intercontinental ballistic missile and satellite reconnaissance capability, but also became part of the cultural symbolism and ideology of the time. The Space Race brought pioneering launches of artificial satellites, robotic landers to the Moon, Venus, and Mars, and human spaceflight in low Earth orbit and ultimately to the Moon. Public interest in space travel originated in the 1951 publication of a Soviet youth magazine and was promptly picked up by US magazines. The competition began on July 29, 1955, when the United States announced its intent to launch artificial satellites for the International Geophysical Year. Five days later, the Soviet Union responded by declaring they would also launch a satellite "in the near future". The launching of satellites was enabled by developments in ballistic missile capabilities since the end of World War II. The competition gained Western public attention with the "Sputnik crisis", when the USSR achieved the first successful satellite launch, Sputnik 1, on October 4, 1957.
Pakistan was among the first nations to establish formal diplomatic ties with China, forging a strong relationship since China's 1962 conflict with India, culminating in a special bond. During the 1970s, Pakistan acted as an intermediary in U.S.-China rapprochement, facilitating US President Richard Nixon's historic visit to China. Despite changes in Pakistani governance and regional/global dynamics, China's influence in Pakistan remains paramount. In reciprocation, China stands as Pakistan's largest trading partner, with substantial investment in Pakistani infrastructure, notably the Gwadar port. In 2015 alone, they inked 51 agreements and Memorandums of Understanding (MoUs) for cooperative efforts. Both nations signed a Free Trade Agreement in 2006, with China making its largest investment in Pakistan's history through CPEC. Pakistan acts as China's liaison to the Muslim world, and both nations support each other on sensitive issues like Kashmir, Taiwan, Xinjiang, and more.
Sources: en.wikipedia.org
== Discovery and development == Tralokinumab was discovered by Cambridge Antibody Technology scientists using protein optimization based on Ribosome Display. They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims. In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005. On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma. In 2016, MedImmune and AstraZeneca started developing tralokinumab for asthma (Phase III) and atopic dermatitis (Phase IIb) while clinical development for moderate-to-severe ulcerative colitis and idiopathic pulmonary fibrosis (IPF) have been discontinued. In July of that year AstraZeneca licensed tralokinumab to Leo Pharma for skin diseases. A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis. In June 2017, Leo Pharma started phase III clinical trials with tralokinumab in atopic dermatitis.
== Financial performance == In 2024, Chick-fil-A reported systemwide sales of $22 billion, ranking it among the top three U.S. restaurant chains by sales, alongside McDonald's ($53.5 billion) and Starbucks ($30.4 billion). The chain achieved this with 3,109 locations, compared to McDonald's 13,559 U.S. locations. Chick-fil-A's average unit volume was $7.5 million per location, the highest among major U.S. fast-food chains.
=== Botanical extracts === When utilized in tincture method extractions, specifically as a 10% solution, glycerol prevents tannins from precipitating in ethanol extracts of plants (tinctures). It is also used as an "alcohol-free" alternative to ethanol as a solvent in preparing herbal extractions. It is less extractive when utilized in a standard tincture methodology. Alcohol-based tinctures can also have the alcohol removed and replaced with glycerol for its preserving properties. Such products are not "alcohol-free" in a scientific or FDA regulatory sense, as glycerol contains three hydroxyl groups. Fluid extract manufacturers often extract herbs in hot water before adding glycerol to make glycerites. When used as a primary "true" alcohol-free botanical extraction solvent in non-tincture based methodologies, glycerol has been shown to possess a high degree of extractive versatility for botanicals including removal of numerous constituents and complex compounds, with an extractive power that can rival that of alcohol and water–alcohol solutions. That glycerol possesses such high extractive power assumes it is utilized with dynamic (critical) methodologies as opposed to standard passive "tincturing" methodologies that are better suited to alcohol. Glycerol does not denature or render a botanical's constituents inert as alcohols (ethanol, methanol, and so on) do.
== Research == Schymanski's first research publications were from her undergraduate work when she worked on developing new metal-containing polymers which resulted in three lead author publications. As a graduate student, Schymanski started using information on the fragmentation pattern of organic compounds as a means to expand the identification of unknown compounds. Schymanski applied these novel methods to the identification of unknown organic compounds found in wastewater, and used data collectively gathered by the NORMAN Association to define barriers to the identification of unknown organic compounds in water. Identifying and tracking unknown organic compounds continues to be an avenue of research pursued by Schymanski and she is a co-author on a 2014 textbook describing these methods. In 2012, Schymanski and Steffen Neumann started the Critical Assessment of Small Molecule Identification (CASMI) contest that provided researchers with information about unknown organic compounds and challenged them to use automated computational tools identify the unknown compounds. The Metabolomics Society highlighted the 2012 contest in their newsletter. There have been multiple iterations of the contest, and Schymanski examined the results of the 2016 contest. Schymanski's research focuses on characterizing organic compounds found in wastewater and exposomics, or the science of compounds that people are exposed to over their lifetimes.
===== Senate allegations ===== In May 2005, a United States Senate committee report accused Galloway and others of receiving, from the Iraqi government, the right to buy oil under the UN's Oil-for-Food Programme. The report was issued by the US Senate Permanent Subcommittee on Investigations, chaired by Senator Norm Coleman, a Republican from Minnesota. Coleman's committee said that Galloway received oil allocations worth 20 million barrels (3,200,000 m3) from 2000 to 2003. The allegations against Galloway, had been made before, including in an October report by US arms inspector Charles Duelfer, as well as in the various purported documents described earlier in this section.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.